摘要
目的:分析低分子肝素联合尿激酶治疗急性心肌梗死的有效性及对患者生活质量的影响。方法:2019年1月-2020年3月收治急性心肌梗死患者47例,随机分为两组。对照组实施基础治疗+尿激酶治疗;试验组在基础治疗+尿激酶基础上联合低分子肝素治疗。比较两组临床疗效。结果:试验组生活质量评分、症状缓解时间、住院时间、治疗优良率及冠状动脉再通率均明显优于对照组,差异有统计学意义(P<0.05)。结论:低分子肝素联合尿激酶治疗急性心肌梗死的有效性较为显著,可改善患者生活质量和临床症状,促进患者预后,并缩短患者住院时间。
Objective:To analyze the curative effect of low molecular heparin combined with urokinase in the treatment of acute myocardial infarction and its effect on the quality of life of patients.Methods:From January 2019 to March 2020,47 cases of patients with acute myocardial infarction were enrolled,they were randomly divided into two groups.The control group was treated with basic treatment combined with urokinase.The experimental group was treated with basic treatment+low molecular heparin combined with urokinase.The therapeutic effects between the two groups was compared.Results:The quality of life score,symptom relief time,the length of hospital stays,the excellent and good rate of treatment and coronary artery recanalization rate in experimental group were better than those of control group,the differences were statistically significant(P<0.05).Conclusion:Low molecular heparin combined with urokinase is effective in the treatment of acute myocardial infarction,which can improve the quality of life and clinical symptoms,promote the prognosis of patients and shorten the length of hospital stays.
作者
孙晓星
Sun Xiaoxing(The Second People's Hospital of Hanchuan City,Hubei Hanchuan 431602)
出处
《中国社区医师》
2021年第5期57-58,共2页
Chinese Community Doctors
关键词
低分子肝素
尿激酶
急性心肌梗死
治疗有效性
生活质量
Low molecular heparin
Urokinase
Acute myocardial infarction
Treatment effectiveness
Quality of life
